Biotech firm Voyager's Q3 collaboration revenue drops, net loss widens

Voyager Therapeutics

10/11/2025 13:09

Overview

Voyager Q3 collaboration revenue falls due to lower Novartis agreement revenue

Net loss widens in Q3 2025 due to increased R&D expenses

Company maintains cash runway into 2028 with $229 mln cash position

Outlook

Voyager anticipates VY1706 clinical trial initiation in 2026

Company expects Neurocrine clinical trial initiations in 2026

Voyager maintains cash runway guidance into 2028

Result Drivers

INCREASED R&D EXPENSES - Higher R&D expenses due to MAD clinical trial for VY7523 and tau silencing gene therapy program VY1706

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Collaboration Revenue
$13.37 mln
Q3 Net Income
-$27.89 mln
Q3 Basic EPS
-$0.47
Q3 Operating Income
-$30.59 mln
Q3 Pretax Profit
-$27.81 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $12.00, about 64.8% above its November 7 closing price of $4.23

Press Release: ID:nGNX79YjJK

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)